Ilpez

Itraconazole, the active ingredient in Ilpez, is an azole antifungal presented as an oral formulation for systemic use. It is employed to treat a range of deep‑tissue fungal infections in adult patients, including those caused by Blastomyces, Histoplasma, Aspergillus and dermatophytes. GNH USA supplies Ilpez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ilpez (itraconazole) is used to manage fungal infections that affect various organ systems. - Systemic mycoses: provides effective therapy for deep‑seated fungal infections. - Blastomycosis: treats infections caused by Blastomyces dermatitidis. - Histoplasmosis: clears infections due to Histoplasma capsulatum. - Aspergillosis: manages invasive disease caused by Aspergillus species. - Dermatophytosis: resolves skin infections caused by dermatophyte fungi.

Adverse reactions to itraconazole may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Elevated liver enzymes: mild, reversible changes in hepatic function tests.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Congestive heart failure: worsening of pre‑existing cardiac conditions. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photophobia. - Hematologic abnormalities: neutropenia or thrombocytopenia.

When prescribing itraconazole, clinicians should consider several safety measures. - Liver function: assess baseline hepatic enzymes and monitor periodically. - Cardiac status: avoid in patients with uncontrolled heart failure. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Renal impairment: adjust therapy if severe renal dysfunction is present. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Itraconazole interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic itraconazole levels. - Certain statins (e.g., simvastatin, lovastatin): increased risk of rhabdomyolysis. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce itraconazole efficacy. - Antacids or H2 blockers: may decrease absorption; separate dosing by at least 2 hours. - Digoxin: possible increase in serum concentration; monitor levels.